First CAR T-Cell Therapy Approved for Solid Tumors
- Study type
- Other
- Study name
- satri-cel
- Phase
- Phase 2
- Design
- News report on a drug approval based on a phase 2 trial (design details not stated in the abstract)
- Sample size
- Not stated in the abstract
- Source
- Cancer Discovery · 2026
In plain words
In China, a cell therapy called CAR-T has been approved for a solid cancer for the first time. It is for some patients with cancer of the stomach or of the junction between the stomach and the oesophagus whose tumour carries the protein claudin 18.2 and does not have HER2. In a study, this treatment lengthened the time without the disease growing and improved survival. However, researchers say more research is still needed to make this approach work better in solid tumours.
Key results
Treatment arms and regimens
Treatment with claudin 18.2-targeted CAR-T cells, satricabtagene autoleucel (satri-cel). Dose details in the full text.
Source of the regimen details: Abstract of the paper
Doses are given for the information of specialists, as in this study’s protocol, and are not a prescription. Every drug must be prescribed by the treating physician for the individual patient.
Study population
Patients with gastric or gastro-oesophageal junction cancer that is claudin 18.2-positive and HER2-negative. Other eligibility criteria are not stated in the abstract.
Endpoints
According to the abstract, the approval was based on progression-free survival and overall survival results from a phase 2 trial. Definitions of the primary and secondary endpoints are not stated in the abstract.
Safety and side effects
No information on adverse events is given in the abstract. Refer to the full trial report.
Clinical significance and place in guidelines
This report describes the approval in China of the first CAR-T therapy for solid tumours. The abstract mentions only the approval in China and gives no information on approval in other countries or its place in clinical guidelines; these should be checked separately. Use of this therapy is limited to claudin 18.2-positive, HER2-negative patients.
Limitations
This is a short news report, not a full trial report. The abstract has no figures, sample size, comparator or safety data. The authors also stress that more research is needed to improve the efficacy of CAR-T in solid tumours.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.